Ademethionine in the treatment of fatigue in liver diseases: a systematic review


Cite item

Full Text

Abstract

Fatigue has a significant effect on the condition of patients with liver disease. Ademethionine is considered one of the most promising drugs for its treatment. Aim. To systematize the published data on the treatment of hepatogenic fatigue with аdemethionine. Materials and methods. Search was performed using databases PubMed, EMBASE, Embase®, Medline®, eLIBRARY.ru, published in 1952-2018. Results and discussion. 16 articles were found on the use of ademethionine in liver diseases and the assessment of the dynamics of the symptom of fatigue, including 1 double-blind, randomized, placebo-controlled study, 3 open randomized studies; most of the works were multicenter open observation programs. The studies included 3238 patients (of which 2820 were included in the final data analysis) and a wide range of liver diseases: alcoholic liver disease, nonalcoholic fatty liver disease, primary biliary cholangitis, primary sclerosing cholangitis, cirrhosis of different causes, viral hepatitis, drug-induced liver injury. Different doses, routes of administration of аdemethionine and the duration of the course were used. Conclusions. Ademethionine, regardless of the route of administration, is effective in the treatment of fatigue due to different liver disease in the short and long term. The dose-dependent effect of the drug and the possibility of maintaining post-effect after end of the treatment course should be assumed, but this requires further study in randomized clinical trials.

About the authors

K L Raikhelson

Saint-Petersburg State University

Email: kraikhelson@mail.ru
д.м.н., проф. научно-клинического и образовательного центра гастроэнтерологии и гепатологии Института высоких медицинских технологий ФГБОУ ВО СПбГУ; тел.: +7(911)911-01-43; ORHID: 0000-0002-8821-6142 Saint Petersburg, Russia

E A Kondrashina

Saint-Petersburg State University

к.м.н., доц. научно-клинического и образовательного центра гастроэнтерологии и гепатологии Института высоких медицинских технологий ФГБОУ ВО СПбГУ; ORHID: 0000-0002-0142-0264 Saint Petersburg, Russia

References

  1. Dantzer R, O’Connor J.C, Freund G.G, Johnson R.W, Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1):46-56. doi: 10.1038/nrn2297
  2. D'Mello C, Swain M.G. Liver - brain interactions in inflammatory liver diseases: implications for fatigue and mood disorders. Brain Behav Immun. 2014;35:9-20. doi: 10.1016/j.bbi.2013.10.009
  3. Newton J, Jones D. Managing systemic symptoms in chronic liver disease. J Hepatol. 2012;56:46-55. doi: 10.1016/s0168-8278(12)60006-3
  4. Swain M.G, Jones D.E.J. Fatigue in chronic liver disease: New insights and therapeutic approaches. Liver Int. 2018. doi: 10.1111/liv [Epub ahead of print]. Accessed 20 October 2018. https://onlinelibrary.wiley.com/doi/full/10.1111/liv.13919
  5. Swain M.G. Fatigue in liver disease: Pathophysiology and clinical management. Can J Gastroenterol. 2006;20(3):181-8. doi: 10.1155/2006/624832
  6. Patidar K.R, Bajaj J.S. Tired of Hepatitis B? Dig Dis Sci. 2016;61(4):953-4. doi: 10.1007/s10620-016-4067-8
  7. Jopson L, Dyson J.K, Jones D.E. Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis. Clin Liver Dis. 2016;20(1):131-42. doi: 10.1016/j.cld.2015.08.007
  8. Elliott C, Frith J, Day C.P, Jones D.E, Newton J.L. Functional impairment in alcoholic liver disease and non - alcoholic fatty liver disease is significant and persists over 3 years of follow - up. Dig Dis Sci. 2013;58(8):2383-91. doi: 10.1007/s10620-013-2657-2
  9. Chen S.S, Yu K.K, Huang C, Li N, Zheng J.M, Bao S.X, Chen M.Q, Zhang W.H. The characteristics and clinical outcome of drug - induced liver injury in a Chinese hospital: A retrospective cohort study. Medicine (Baltimore). 2016;95(34):e4683. doi: 10.1097/md.0000000000004683
  10. Hickman I.J, Jonsson J.R, Prins J.B, Ash S, Purdie D.M, Clouston A.D, Powell E.E. Modest weight loss and physical activity in over - weight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut. 2004;53:413-9. doi: 10.1136/gut.2003.027581
  11. Melles G.F, Pells G, Newton J.L, Bathgate A.J, Burroughs A.K, Heneghan M.A, Neuberger J.M, Day D.B, Ducker S.J, Sandford R.N, Alexander G.J, Jones D.E. Impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study. Hepatology. 2013;58(1):273-83. doi: 10.1002/hep.26365
  12. Cauch-Dudek K, Abbey S, Stewart D.E, Heathcote E.J. Fatigue in primary biliary cirrhosis. Gut. 1998;43(5):705-10. doi: 10.1136/gut.43.5.705
  13. Jones D.E. Fatigue in cholestatic liver disease: Is it all in the mind? J Hepatol. 2007;46:992-4. doi: 10.1016/j.jhep.2007.03.006
  14. Newton J.L, Jones D.E.J, Henderson E, Kane L, Wilton K, Burt A.D, Day C.P. Fatigue in non - alcoholic fatty liver disease is severe and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008;57:807-13. doi: 10.1136/gut.2007.139303
  15. Newton J.L. Systemic Symptoms in Non-Alcoholic Fatty Liver Disease. Dig Dis. 2010;28:214-9. doi: 10.1159/000282089
  16. Jones D.E, Bhala N, Burt J, Goldblatt J, Prince M.I, Newton J.L. Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Gut. 2006;55(4):536-41. doi: 10.1136/gut.2005.080317
  17. Werner M, Wallerstedt S, Lindgren S, Almer S, Bjornsson E, Bergquist A. Characteristics and long - term outcomes of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol. 2010;45:457-67. doi: 10.3109/00365520903555861
  18. Jones D.E.J, Al-Rifai A, Frith J, Patanwala I, Newton J.L. The independent effects of fatigue and UDCA therapy on mortality in primary biliary cirrhosis: Results of a 9 year follow - up. J Hepatol. 2010;53:911-7. doi: 10.1016/j.jhep.2011.05.001
  19. Bona M.D, Ponton P, Ermani M, Lemmolo R.M, Feltrin A, Boccagni P, Gerunda G, Naccarato R, Rupolo G, Burra P. The impact of liver disease and medical complications on quality of life and psychological distress before and after liver transplantation. J Hepatol. 2000;33:609-15. doi: 10.1034/j.1600-0641.2000.033004609.x
  20. Van Ginneken B.T.J, van den Berg-Emons R.J.G, van der Windt A, Tilanus H.W, Metselaar H.J, Stam H.J, Kazemier G. Persistent fatigue in liver transplant recipients: a two year follow - up study. Clin Transpl. 2010;24:10-6. doi: 10.1111/j.1399-0012.2009.01083.x
  21. Mücke M, Mochamat, Cuhls H, Peuckmann-Post V, Minton O, Stone P, Radbruch L. Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review. J Cachexia Sarcopenia Muscle. 2016;7(1):23-7. doi: 10.1002/jcsm.12101
  22. Барановский А.Ю., Райхельсон К.Л., Марченко Н.В. Применение S-аденозилметионина (Гептрала®) в терапии больных неалкогольным стеатогепатитом. Клинические перспективы гастроэнтерологии, гепатологии. 2010;9(1):3-10.
  23. Райхельсон К.Л., Мительглик У.А., Зубарева А.С., Марченко Н.В., Семенов Н.В., Барановский А.Ю. Принципы и перспективы лечения первичного билиарного цирроза. Экспериментальная и клиническая гастроэнтерология. 2012;(3):90-5.
  24. Virukalpattigopalratnam M.P, Singh T, Ravishankar A.C. Heptral® (Ademetionine) in Intrahepatic Cholestasis due to Chronic Non-Alcoholic Liver Disease: Subgroup Analysis of Results of a Multicentre Observational Study in India. J Clin Exper Hepatol. 2014;4(Suppl. 2):S33 doi: 10.1016/j.jceh.2014.02.071
  25. Perlamutrov Y, Bakulev A, Korsunskaya I, Orlov E, Bolotnikova N. Ademetionine in treatment of drug induced liver injury: an observational study in Russian patients, receiving immunosuppressive therapy for psoriasis. Int J Pharm Sci Res. 2014;5(12):5163-9. doi: 10.13040/IJPSR.0975-8232.5(12).5163-5169
  26. Choudhuri, G., Singh, T. Heptral® (Ademetionine) in patients with chronic alcoholic liver disease: Results of a multicenter observational study in Indian patients. Int J Res Health Sci [Online]. 2014;2(3):831-41 (Accessed October 6, 2018). http://www.ijrhs.com/issues.php?val=Volume2&iss=Issue3
  27. Снеговой А.В., Ларионова В.Б., Зейналова П.А., Манзюк Л.В., Крейнина Ю.М., Кагония Л.М. Окончательные результаты проспективной многоцентровой программы Р12-717 (применение Гептрала при хронической болезни печени, обусловленной лекарственно - индуцированным поражением печени вследствие химиотерапии). Вестник РОНЦ им. Н.Н. Блохина РАМН. 2016;27(2):142-56.
  28. Бутов М., Василевская А., Мнихович М., Маслова О. Адеметионин при алкоголь ассоциированных заболеваниях печени: клинико - экспериментальное исследование. Врач. 2014;(6):49-52.
  29. Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di Padova C. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis. Gastroenterology. 1990;99(1):211-5. doi: 10.1016/0016-5085(90)91250-a
  30. Fiorelli G. S-Adenosylmethionine in the treatment of intrahepatic cholestasis of chronic liver disease: A field trial. Curr Ther Res. 1999;60(6):335-48. doi: 10.1016/s0011-393x(99)80010-1
  31. Di Perri T, Sacco T, Festi D. The SMACK Investigator Group. Ademetionine in the treatment of chronic hepatic disease. Gastroenterol Int. 1999;12(2):62-8.
  32. Подымова С.Д., Надинская М.Ю. Оценка эффективности препарата Гептрал у больных хроническими диффузными заболеваниями печени с синдромом внутрипеченочного холестаза. Клиническая медицина. 1998;76(10):45-8.
  33. Wang Bao-En. Ademetionine 1,4 Butanedisulphonate vs Traditional Chinese Medicine for the Treatment of Hepatocellular Jaundice Complicating Chronic Viral Hepatitis. Clin Drug Investigat. 2001;21(11):765-73. doi: 10.2165/00044011-200121100-00004
  34. Wang Bao-En. Ademetionine 1,4-Butanedisulphonate vs Traditional Chinese Medicine for the Treatment of Acute Viral Hepatitis with Hepatocellular Jaundice. Clin Drug Investigat. 2001;21(10):685-94. doi: 10.2165/00044011-200121100-00003
  35. Харченко Н.В. Адеметионин в лечении внутрипеченочного холестаза в рутинной клинической практике в Украине: проспективное постмаркетинговое обсервационное исследование. Сучасна Гастроентерологія. 2013;5(73):60-8.
  36. Ivashkin V.T, Maevskaya M.V, Kobalava Z.D, Uspenskiy Y.P, Fominih J.A, Rozanov A.V, Tolkacheva V.V, Sotnikova T, Alikhanov B.A, Gorbacheva I.A, Ershova O.B, Znakhyrenko A.A, Sokolov K.A, Sander-Struckmeier S. Open - label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. Minerva Gastroenterol Dietol. 2018;64(3):208-19. doi: 10.23736/S1121-421X.18.02461-3
  37. Митин М.С. Применение адеметионина (гептрал) для терапии астеновегетативного синдрома у больных хроническим вирусным гепатитом С. Научные ведомости БелГУ Серия: Медицина. Фармация. 2014;11(182):68-71.
  38. Wunsch E, Raszeja-Wyszomirska J, Barbier O, Milkiewicz M, Krawczyk M, Milkiewicz P. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study. J Gastrointestin Liver Dis. 2018;27(3):273-9. doi: 10.15403/jgld.2014.1121.273.icz
  39. Austin P.W, Gerber L, Karrar A.K. Fatigue in chronic liver disease: exploring the role of the autonomic nervous system. Liver Int. 2015;35(5):1489-91. doi: 10.1111/liv.12784
  40. Miller A.H, Haroon E, Raison C.L, Felger J.C. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30(4):297-306. doi: 10.1002/da.22084
  41. Grover V.P, Southern L, Dyson J.K, Kim J.U, Crossey M.M.E, Wylezinska-Arridge M, Patel N. Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging. Aliment Pharmacol Ther. 2016;44 (9):936-45. doi: 10.1111/apt.13797
  42. Mosher V.A.L, Swain M.G, Pang J.X.Q, Kaplan G.G, Sharkey K.A, Mac Queen G.M, Goodyear B.J. Primary Biliary Cholangitis Alters Functional Connections of the Brain's Deep Gray Matter. Clin Transl Gastroenterol. 2017;8(7):e107. doi: 10.1038/ctg.2017.34
  43. D’Mello C, Swain M.G. Immune - to-Brain Communication Pathways in Inflammation-Associated Sickness and Depression. Curr Top Behav Neurosci. 2017;31:73-94. doi: 10.1007/7854_2016_37
  44. Capuron L, Miller A.H. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130(2):226-38. doi: 10.1016/j.pharmthera.2011.01.014
  45. Hermann G.E, Rogers R.C. TNF-alpha: a trigger of autonomic dysfunction. Neuroscientist. 2008;14(1):53-67. doi: 10.1177/1073858407305725
  46. Syngle A, Verma I, Krishan P, Garg N, Syngle V. Disease - modifying anti - rheumatic drugs improve autonomic neuropathy in arthritis: DIANA study. Clin Rheumatol. 2015;34(7):1233-41. doi: 10.1007/s10067-014-2716-x
  47. Gruys E, Toussaint M.J.M, Niewold T.A, Koopmans S.J. Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci. 2005;6:1045-56. doi: 10.1631/jzus.2005.b1045
  48. Kerfoot S.M, D’Mello C, Nguyen H, Ajuebor M.N, Kubes P, Le T, Swain M.G. TNF-α secreting monocytes are recruited into the brains of cholestatic mice. Hepatology. 2006;43:154-62. doi: 10.1002/hep.21003
  49. Kobayashi Y. The regulatory role of nitric oxide in proinflammatory cytokine expression during the induction and resolution of inflammation. J Leukoc Biol. 2010;88:1157-62. doi: 10.1189/jlb.0310149
  50. Nadeau S, Rivest S. Effects of circulating tumor necrosis factor - a on the neuronal activity and expression of the genes encoding the tumor necrosis factor receptors (p55 and p75) in the rat brain: a view from the blood - brain barrier. Neuroscience. 1999;93:1449-64. doi: 10.1016/s0306-4522(99)00225-0
  51. Thibeault I, Laflamme N, Rivest S. Regulation of the gene encoding the Monocyte Chemoattractant Protein 1 (MCP-1) in the mouse and rat brain in response to circulating LPS and proinflammatory cytokines. J Comp Neurol. 2001;434:461-77. doi: 10.1002/cne.1187
  52. D’Mello C, Le T, Swain M. Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factor signaling during peripheral organ inflammation. J Neurosci. 2009;29:2089-102. doi: 10.1523/jneurosci.3567-08.2009
  53. D’Mello C, Riazi K, Le T, Stevens K.M, Wang A, Mc Kay D.M.Q, Pittman J, Swain M.G. P-selectin - mediated monocyte - cerebral endothelium adhesive interactions link peripheral organ inflammation to sickness behaviors. J Neurosci. 2013;33(37):14878-88. doi: 10.1523/jneurosci.1329-13.2013
  54. Anstee Q.M, Day C.P. S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility. J Hepatol. 2012;57(5):1097-109. doi: 10.1016/j.jhep.2012.04.041
  55. Mato J.M, Martinez-Chantar M.L, Shelly C.L. S-adenosylmethionine metabolism and liver disease. Ann Hepatol. 2013;12(2):183-9.
  56. Chawla R.K, Watson W.H, Eastin C.E, Lee E.Y, Schmidt J, Mc Clain C.J. S-adenosylmethionine deficiency and TNF-alpha in lipopolysaccharide - induced hepatic injury. Am J Physiol. 1998;275(1 Pt 1):G125-9.
  57. Mc Clain C.J, Hill D.B, Song Z, et al. S-Adenosylmethionine, cytokines, and alcoholic liver disease. Alcohol. 2002;27(3):185-92.
  58. Veal N, Hsieh C.L, Xiong S, et al. Inhibition of lipopolysaccharide - stimulated TNF-alpha promoter activity by S-adenosylmethionine and 5'-methylthioadenosine. Am J Physiol Gastrointest Liver Physiol. 2004;287(2):G352-62. doi: 10.1152/ajpgi.00316.2003
  59. Song Z, Uriarte S, Sahoo R, Chen T, Barve S, Hill D, Mc Clain C. S-adenosylmethionine (SAMe) modulates interleukin-10 and interleukin-6, but not TNF, production via the adenosine (A2) receptor. Biochim Biophys Acta. 2005;1743:205-13. doi: 10.1016/j.bbamcr.2004.12.001
  60. Ara A.I, Xia M, Ramani K, Mato J.M, Lu S.C. S-adenosylmethionine inhibits lipopolysaccharide - induced gene expression via modulation of histone methylation. Hepatology. 2008;47(5):1655-66. doi: 10.1002/hep.22231
  61. Gong Z, Yan S, Zhang P, Huang Y, Wang L. Effects of S-adenosylmethionine on liver methionine metabolism and steatosis with ethanol - induced liver injury in rats. Hepatol Int. 2008;2(3):346-52. doi: 10.1007/s12072-008-9082-1
  62. Pfalzer A.C, Choi S.W, Tammen S.A, Park L.K, Bottiglieri T, Parnell L.D. S-adenosylmethionine mediates inhibition of inflammatory response and changes in DNA methylation in human macrophages. Physiol Genom. 2014;46(17):617-23. doi: 10.1152/physiolgenomics.00056.2014
  63. Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter L.L, Lavretsky H, Muskin P.R, Brown R.P, Mischoulon D; as Work Group of the American Psychiatric Association Council on Research. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J Clin Psychiatry. 2017;78(6):e656-e667. doi: 10.4088/JCP.16r11113

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies